Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advaxis, Amplyx, Biomarin, Cadila, Cassiopea, Cava, Cosmo, Hyloris, Iktos, Kineta, Lipidor, Mynd, Pfizer, Providence, Purdue, Skyline, Vaneltix, Vera.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Albireo, Alligator, Apnimed, Applied, Aptinyx, Arcturus, Attralus, Axcella, Celyad, Cullinan, Debiopharm, Denovo, Diffusion, Douglas, Emergent, Ensysce, Fortress, In8bio, Innate, Kodiak, Kura, Kymera, Mallinckrodt, Matinas, Navidea, Nicox, Novaliq, Proqr, Seres, Uniqure, Valneva, Zealand.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Firstkind, Implicity, Roche, Sky Medical Technology.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Applied Biocode, Fist Assist, Mdoloris, Mindray.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 60 Degrees, Aerovate, Amgen, Arthrosi, Artax, Bioxcel, City of Hope, Eiger, Eli Lilly, Enbiotix, Exelixis, Geovax, GSK, Idera, Jazz, Nektar, NFL, Pharma Two, Polyphor, Recce, Sanofi, Sumitomo, Travere, Ultimovacs, Varmx.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apellis, Boehringer, CSL, Everest, Fate, I-Mab, Incyte, J&J, Laurent, Merck, Nuvation, Sapience, Sobi.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acurastem, Alpine Immune, Amgen, Anabio, Antares, Antengene, Aperion, Aqemia, Argobio, Assertio, Astrazeneca, BCI, Cerevel, Evofem, Evotec, Genecode, Herophilus, Horizon, ICER, Inceptor, Metrion, Mithra, Orion, Poolbeg, SAB, Servier, Sosei, Twist, Vaxart, Verona, Xtalpi.

Vaccine specialists Sanofi SA and Glaxosmithkline plc have been behind the curve throughout the pandemic, with upstarts such as Moderna Inc. and Biontech SE stealing the show with their ground-breaking mRNA technology. While their rivals were beginning to launch the first wave of vaccines early last year, Sanofi and GSK had to reformulate theirs after it failed to produce a strong enough immune response in older people. New results show that the shot, SP-0253, could play a role as a booster but there will be another delay after the companies struggled to recruit enough participants in a crucial phase III trial.